EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease

Dylan M Johnson iD, Terry Juelich iD, Lihong Zhang, Jennifer K Smith, Birte K Kalveram, David Perez, Jeanon Smith iD, Michael R Grimes, Tania Garron, Maricela Torres, Shane Massey, Trevor Brasel und 3 weitere

Viruses · 2024

DOI: 10.3390/v16071101 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Viruses, 2024. Verfasst von Dylan M Johnson und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA. Hauptthemen laut MEDLINE: Amides, Pyrazines, Hemorrhagic Fever, Ebola, Disease Models, Animal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Favipiravir is a ribonucleoside analogue that has been explored as a therapeutic for the treatment of Ebola Virus Disease (EVD). Promising data from rodent models has informed nonhuman primate trials, as well as evaluation in patients during the 2013–2016 West African EVD outbreak of favipiravir treatment. However, mixed results from these studies hindered regulatory approval of favipiravir for the indication of EVD. This study examined the influence of route of administration, duration of treatment, and treatment schedule of favipiravir in immune competent mouse and guinea pig models using rodent-adapted Zaire ebolavirus (EBOV). A dose of 300 mg/kg/day of favipiravir with an 8-day treatment was found to be fully effective at preventing lethal EVD-like disease in BALB/c mice regardless of route of administration (oral, intraperitoneal, or subcutaneous) or whether it was provided as a once-daily dose or a twice-daily split dose. Preclinical data generated in guinea pigs demonstrates that an 8-day treatment of 300 mg/kg/day of favipiravir reduces mortality following EBOV challenge regardless of route of treatment or duration of treatments for 8, 11, or 15 days. This work supports the future translational development of favipiravir as an EVD therapeutic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmidesPyrazinesHemorrhagic Fever, EbolaDisease Models, AnimalEbolavirusAntiviral AgentsMice, Inbred BALB CAnimalsGuinea PigsMiceFemaleDrug Administration RoutesDrug Administration Schedule

Stichwörter der Autor:innen

EBOVEbola virusT-705animal modelfavipiravirfilovirus

Substanzen

favipiravirAmidesPyrazinesAntiviral Agents

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
  • Department of Biotechnology & Bioengineering, Sandia National Laboratories, Livermore, CA 945501, USA.
  • Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
  • Office of Biosafety, Texas A&M University, College Station, TX 77843, USA.
  • Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
  • Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist, Houston, TX 77030, USA.

ORCID-Profile: Dylan M Johnson, Terry Juelich, Jeanon Smith, Alex N Freiberg

Förderung

  • the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services
  • Preclinical Models of Infectious Diseases Task Order
  • UTMB internal funding

Zitieren

APA

Johnson, D. M., Juelich, T., Zhang, L., Smith, J. K., Kalveram, B. K., Perez, D., Smith, J., Grimes, M. R., Garron, T., Torres, M., Massey, S., Brasel, T., Beasley, D. W. C., Freiberg, A. N., & Comer, J. E. (2024). Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease. Viruses. https://doi.org/10.3390/v16071101

Vancouver

Johnson DM, Juelich T, Zhang L, Smith JK, Kalveram BK, Perez D, et al. Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease. Viruses. 2024. doi:10.3390/v16071101

BibTeX
@article{Johnson2024,
  author = {Johnson, Dylan M and Juelich, Terry and Zhang, Lihong and Smith, Jennifer K and Kalveram, Birte K and Perez, David and Smith, Jeanon and Grimes, Michael R and Garron, Tania and Torres, Maricela and Massey, Shane and Brasel, Trevor and Beasley, David W C and Freiberg, Alex N and Comer, Jason E},
  title = {Comparison of Routes of Administration, Frequency, and Duration of Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16071101}
}
Kostenlos starten →